Global Deuterated Drugs Market Research Report 2024
Published on: 2024-01-04 | No of Pages : 400 | Industry : Latest Trends
Publisher : MRA | Format : PDF
Global Deuterated Drugs Market Research Report 2024
A deuterated drug is a small molecule medicinal product in which one or more of the hydrogen atoms contained in the drug molecule have been replaced by its heavier stable isotope deuterium. Because of the kinetic isotope effect, deuterium-containing drugs may have significantly lower rates of metabolism, and hence a longer half-life.
According to MRA Research’s new survey, global Deuterated Drugs market is projected to reach US$ million in 2033, increasing from US$ million in 2023, with the CAGR of % during the period of 2023 to 2033. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Deuterated Drugs market research.
Key companies engaged in the Deuterated Drugs industry include Teva, Suzhou Zelgen Biopharmaceuticals, Concert Pharmaceuticals, Vertex Pharmaceuticals, Hinova Pharma, Otsuka Pharmaceutical (Avanir) and Poxel SA (DeuteRx), etc. Among those companies, the top 3 players guaranteed % supply worldwide in 2023.
When refers to consumption region, % value of Deuterated Drugs were sold to North America, Europe and Asia Pacific in 2023. Moreover, China, plays a key role in the whole Deuterated Drugs market and estimated to attract more attentions from industry insiders and investors.
Report Scope
This report, based on historical analysis (2018-2023) and forecast calculation (2023-2033), aims to help readers to get a comprehensive understanding of global Deuterated Drugs market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
![](http//localhost/mraccuracy/images/Market%20Recearch%20Graph.jpg)
Teva
Suzhou Zelgen Biopharmaceuticals
Concert Pharmaceuticals
Vertex Pharmaceuticals
Hinova Pharma
Otsuka Pharmaceutical (Avanir)
Poxel SA (DeuteRx)
Segment by Type
Austedo
Zepsun
Others
Huntington'S Disease (HD)
Tardive Dyskinesia (TD)
Cancer
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Deuterated Drugs report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Global market size, regional market size. Market Opportunities and Challenges
Chapter 3Companies’ Competition Patterns
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6 to 10Country Level Value Analysis
Chapter 11Companies' Outline
Chapter 12Market Conclusions
Chapter 13Research Methodology and Data Source![](http://localhost/mraccuracy/images/About Report.webp)
According to MRA Research’s new survey, global Deuterated Drugs market is projected to reach US$ million in 2033, increasing from US$ million in 2023, with the CAGR of % during the period of 2023 to 2033. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Deuterated Drugs market research.
Key companies engaged in the Deuterated Drugs industry include Teva, Suzhou Zelgen Biopharmaceuticals, Concert Pharmaceuticals, Vertex Pharmaceuticals, Hinova Pharma, Otsuka Pharmaceutical (Avanir) and Poxel SA (DeuteRx), etc. Among those companies, the top 3 players guaranteed % supply worldwide in 2023.
When refers to consumption region, % value of Deuterated Drugs were sold to North America, Europe and Asia Pacific in 2023. Moreover, China, plays a key role in the whole Deuterated Drugs market and estimated to attract more attentions from industry insiders and investors.
Report Scope
This report, based on historical analysis (2018-2023) and forecast calculation (2023-2033), aims to help readers to get a comprehensive understanding of global Deuterated Drugs market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
![](http//localhost/mraccuracy/images/Market%20Recearch%20Graph.jpg)
By Company
Teva
Suzhou Zelgen Biopharmaceuticals
Concert Pharmaceuticals
Vertex Pharmaceuticals
Hinova Pharma
Otsuka Pharmaceutical (Avanir)
Poxel SA (DeuteRx)
Segment by Type
Austedo
Zepsun
Others
Segment by Application
Huntington'S Disease (HD)
Tardive Dyskinesia (TD)
Cancer
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Deuterated Drugs report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Global market size, regional market size. Market Opportunities and Challenges
Chapter 3Companies’ Competition Patterns
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6 to 10Country Level Value Analysis
Chapter 11Companies' Outline
Chapter 12Market Conclusions
Chapter 13Research Methodology and Data Source
![](http://localhost/mraccuracy/images/About Report.webp)